Published in Schweiz Med Wochenschr on March 19, 1977
Nonspecific small bowel ulceration. Postgrad Med J (1985) 0.90
Effects on upper gastrointestinal mucosa of three delivery systems of potassium as supplement to frusemide administration. J R Soc Med (1985) 0.85
Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum (2003) 2.51
Phagolysosomal pH of human neutrophils. Blood (1984) 1.75
Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet (1985) 1.70
Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol (1999) 1.63
Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol (1996) 1.50
Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Ther (1980) 1.44
Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol (1984) 1.35
Central analgesic effect of acetaminophen but not of aspirin. Clin Pharmacol Ther (1991) 1.30
Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res (1998) 1.29
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol (1986) 1.23
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J (2008) 1.23
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
[Pharmacokinetics of a new cephalosporin, cefoperazone]. Schweiz Med Wochenschr (1979) 1.20
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol (2010) 1.15
Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci (1993) 1.14
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica (1986) 1.14
Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther (1985) 1.12
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
Heterogeneity of human neutrophil phagolysosomes: functional consequences for candidacidal activity. Blood (1984) 1.08
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol (2010) 1.06
CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2). J Pathol (2007) 1.05
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther (1999) 1.05
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol (1996) 1.05
Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol (1991) 1.05
Hereditary myeloperoxidase deficiency. Blood (1979) 1.04
Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer (2000) 1.03
High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res (2000) 1.03
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther (1998) 1.03
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther (1995) 0.99
The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet (1982) 0.99
Lack of acetaminophen ceiling effect on R-III nociceptive flexion reflex. Eur J Clin Pharmacol (1998) 0.99
Leukocyte myeloperoxidase deficiency and diabetes mellitus associated with Candida albicans liver abscess. Am J Med (1979) 0.98
A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res (1993) 0.96
Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer (1999) 0.95
Clinical pharmacology and rationale of analgesic combinations. Eur J Anaesthesiol Suppl (2003) 0.94
Stereoselective interaction between piroxicam and acenocoumarol. Br J Clin Pharmacol (1996) 0.93
[The surname of Adamkiewicz in the medical terminology in the last three decades of the 20th century]. Arch Hist Filoz Med (2001) 0.92
Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett (1984) 0.92
Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol (1982) 0.91
In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol (1991) 0.90
N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics (1998) 0.90
Metabolic genetic polymorphisms and susceptibility to lung cancer. Lung Cancer (2001) 0.89
Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother (1996) 0.89
Effects of beta-blockade on energy metabolism following burns. Burns (1990) 0.88
Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. Pharmacogenetics (1998) 0.87
Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. Eur J Clin Pharmacol (1992) 0.87
Simultaneous tubular excretion and reabsorption of pindolol in man. Eur J Clin Pharmacol (1981) 0.87
[Duality of the analgesic effect of tramadol in humans]. Schweiz Med Wochenschr (1993) 0.86
Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev (1998) 0.85
Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents. Clin Pharmacokinet (1980) 0.85
Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 0.84
Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab (2010) 0.84
Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther (2012) 0.84
Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. Eur J Clin Pharmacol (1990) 0.83
Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agents Chemother (1992) 0.83
Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol (1985) 0.83
Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol (1996) 0.83
Radiation recall in a patient with breast cancer treated for tuberculosis. Eur J Clin Pharmacol (1995) 0.82
Contribution of cytochrome P-4502D6 phenotype to the neuromodulatory effects of dextromethorphan. J Pharmacol Exp Ther (1999) 0.82
Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.82
Polymorphism in drug metabolism. Br Med J (1978) 0.81
The effects of biliary obstruction on excretion of cefoperazone in the rat. Arzneimittelforschung (1984) 0.81
The genetic control of drug oxidation in the liver. Int J Clin Pharmacol Res (1983) 0.81
Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics (1999) 0.81
The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro. Br J Pharmacol (2012) 0.81
Function of human alveolar macrophages after a 3-day course of azithromycin in healthy volunteers. Pulm Pharmacol Ther (1998) 0.80
Propranolol treatment in children with tetralogy of Fallot alters the response to isoprenaline after surgical repair. Br Heart J (1988) 0.80
In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. Life Sci (1992) 0.80
Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers. Clin Pharmacol Ther (1993) 0.80
Serum protein binding of diazepam and propranolol in the feto-maternal unit from early to late pregnancy. Br J Obstet Gynaecol (1986) 0.80
Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol (1986) 0.80
[Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation]. Schweiz Med Wochenschr (1983) 0.80
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol (1985) 0.80
Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.80
Simultaneous stereoselective analysis of tramadol and its main phase I metabolites by on-line capillary zone electrophoresis-electrospray ionization mass spectrometry. J Chromatogr A (2000) 0.80
Objective assessment of clonidine analgesia in man and influence of naloxone. Life Sci (1990) 0.80
Morphology and some biomechanical properties of human liver and spleen. Surg Radiol Anat (2002) 0.79
Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers. Biochem Biophys Res Commun (1984) 0.79
Laparoscopic cholecystectomy through prolene mesh after bilateral TRAM flap. Plast Reconstr Surg (1997) 0.79
Interindividual pharmacokinetic and pharmacodynamic variability of different beta blockers. J Cardiovasc Pharmacol (1986) 0.79
[Clinical pharmacology in practice]. Schweiz Med Wochenschr (1994) 0.79
Effects of phorbol diesters and teleocidin on normal human platelets. Thromb Res (1986) 0.78
Effects of glutathione S-transferases GSTM1 and GSTT1 genotypes on lung cancer risk in smokers. Pharmacogenetics (1997) 0.78
High- and low-affinity receptors regulate platelet responses to phorbol diesters and teleocidin. Thromb Res (1987) 0.78
Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol (1996) 0.78
Lack of interaction of the NMDA receptor antagonists dextromethorphan and dextrorphan with P-glycoprotein. Curr Drug Metab (2008) 0.78
Oxygen metabolism of phagocytosing human polymorphonuclear leucocytes in diabetes mellitus. Blut (1984) 0.78
The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res (1996) 0.78
CYP2D6 gene polymorphism in caucasian smokers: lung cancer susceptibility and phenotype-genotype relationships. Eur J Cancer (2000) 0.78
Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide. Life Sci (1994) 0.78
Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Arch Psychiatr Nervenkr (1970) (1982) 0.77
CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population. Biomarkers (1997) 0.77
Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers. Clin Pharmacol Ther (1987) 0.77
Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol. Eur J Clin Pharmacol (1993) 0.77
Use of the label "litigation neurosis" in patients with somatoform pain disorder. Gen Hosp Psychiatry (1998) 0.77
[Comparison of four drug interaction screening programs]. Rev Med Suisse (2012) 0.77
[Predictive factors of resistance to treatment of neuropathic pain]. Schweiz Med Wochenschr (1994) 0.77
Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet (2001) 0.77
Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics (1997) 0.77